Unibest 优贝德
登录 / 注册
← 返回专利悬崖列表

CAS 155619-42-4

(1'S,3'S,4'S,7'R,9'S,10'S)-4',9'-bis[(tert-butyldimethylsilyl)oxy]-1'-(methoxymethoxy)-10',14',17',17'-tetramethyl-6'-oxaspiro[1,3-dithiane-2,12'-tetracyclo[11.3.1.0(3,10).0(4,7)]heptadecan]-13'-ene-2',11'-dione

登记编号:(XIX)101438-16-a,(XIX)101438-16-b

应用背景(按来源药适应症)

乳腺癌Paclitaxel/Encequidar mesylate腺癌Paclitaxel/Encequidar mesylate血管肉瘤Paclitaxel/Encequidar mesylate实体瘤Paclitaxel/Encequidar mesylate

来源药(使用该中间体的合成路线)

品种梯队到期年
Paclitaxel/Encequidar mesylatePaclitaxel/Encequidar mesylateTier C · 观察 / 贸易-

合成路线中的位置(上下游链)

按路线登记顺序排列,左→右为合成方向;高亮为当前 CAS,其余可点击跳转对应档案。

Paclitaxel/Encequidar mesylate优化路线步数:16总收率:/
(4'aS,5'S)-4'a-methyl-3',4',4'a,5',6',7'-hexahydro-1'H-spiro[1,3-dioxolane-2,2'-naphthalene]-5'-ol→[(4'aS,5'S)-4'a-methyl-3',4',4'a,5',6',7'-hexahydro-1'H-spiro[1,3-dioxolane-2,2'-naphthalene]-5'-yloxy](tert-butyl)dimethylsilane→(4'aS,5'S,8'aS)-5'-[(tert-butyldimethylsilyl)oxy]-4'a-methyl-octahydro-1'H-spiro[1,3-dioxolane-2,2'-naphthalene]-8'-one→(4'aS,5'S,8'aS)-5'-[(tert-butyldimethylsilyl)oxy]-4'a-methyl-3',4',4'a,5',6',8'a-hexahydro-1'H-spiro[1,3-dioxolane-2,2'-naphthalene]-8'-yl trifluoromethanesulfonate→(1S,2S,5R,7S,8S)-7-[(tert-butyldimethylsilyl)oxy]-2-hydroxy-8-methyl-4-oxatricyclo[6.4.0.0(2,5)]dodecan-11-one→methyl (4'aS,5'S,8'aS)-5'-[(tert-butyldimethylsilyl)oxy]-4'a-methyl-3',4',4'a,5',6',8'a-hexahydro-1'H-spiro[1,3-dioxolane-2,2'-naphthalene]-8'-carboxylate→(4'aS,5'S,8'aR)-5'-[(tert-butyldimethylsilyl)oxy]-4'a-methyl-3',4',4'a,5',6',8'a-hexahydro-1'H-spiro[1,3-dioxolane-2,2'-naphthalene]-8'-ylmethanol→(4'aS,5'S,7'R,8'S,8'aS)-5'-[(tert-butyldimethylsilyl)oxy]-8'-(hydroxymethyl)-4'a-methyl-octahydro-1'H-spiro[1,3-dioxolane-2,2'-naphthalene]-7',8'-diol→(1'S,2'S,5'R,7'S,8'S)-7'-[(tert-butyldimethylsilyl)oxy]-8'-methyl-4'-oxaspiro[1,3-dioxolane-2,11'-tricyclo[6.4.0.0(2,5)]dodecane]-2'-ol→(1S,2S,5R,7S,8S)-7-[(tert-butyldimethylsilyl)oxy]-2-hydroxy-8-methyl-4-oxatricyclo[6.4.0.0(2,5)]dodec-9-en-11-one→(1S,2S,5R,7S,8S)-2,7-bis[(tert-butyldimethylsilyl)oxy]-8-methyl-4-oxatricyclo[6.4.0.0(2,5)]dodec-9-en-11-one→(1S,2S,3S,4S,6R)-1,4-bis[(tert-butyldimethylsilyl)oxy]-3-methyl-7-oxabicyclo[4.2.0]octane-2,3-dicarbaldehyde→(1S,2S,3S,4S,6R)-1,4-bis[(tert-butyldimethylsilyl)oxy]-2-(1,3-dioxolan-2-yl)-3-methyl-7-oxabicyclo[4.2.0]octane-3-carbaldehyde→[2-(2,4-dimethylpenta-1,3-dien-3-yl)-1,3-dithian-2-yl]lithium→(1'S,3'S,4'S,7'R,9'S,10'S)-4',9'-bis[(tert-butyldimethylsilyl)oxy]-1'-(methoxymethoxy)-10',14',17',17'-tetramethyl-6'-oxaspiro[1,3-dithiane-2,12'-tetracyclo[11.3.1.0(3,10).0(4,7)]heptadecan]-13'-ene-2',11'-dione→tert-butyl({[(1S,2S,3S,4S,6R)-4-[(tert-butyldimethylsilyl)oxy]-3-{[2-(2,4-dimethylpenta-1,3-dien-3-yl)-1,3-dithian-2-yl]carbonyl}-2-(1,3-dioxolan-2-yl)-3-methyl-7-oxabicyclo[4.2.0]octan-1-yl]oxy})dimethylsilane→(1S,2S,3S,4S,6R)-1,4-bis[(tert-butyldimethylsilyl)oxy]-3-{[2-(2,4-dimethylpenta-1,3-dien-3-yl)-1,3-dithian-2-yl]carbonyl}-3-methyl-7-oxabicyclo[4.2.0]octane-2-carbaldehyde→1-lithio-1-(methoxymethoxy)ethene→1-[(1S,2S,3S,4S,6R)-1,4-bis[(tert-butyldimethylsilyl)oxy]-3-{[2-(2,4-dimethylpenta-1,3-dien-3-yl)-1,3-dithian-2-yl]carbonyl}-3-methyl-7-oxabicyclo[4.2.0]octan-2-yl]-2-(methoxymethoxy)prop-2-en-1-one→1,2-Dihydroxyethane
Paclitaxel/Encequidar mesylate优化路线步数:8总收率:/
(1'S,3'S,4'S,7'R,9'S,10'S)-4',9'-bis[(tert-butyldimethylsilyl)oxy]-1'-(methoxymethoxy)-10',14',17',17'-tetramethyl-6'-oxaspiro[1,3-dithiane-2,12'-tetracyclo[11.3.1.0(3,10).0(4,7)]heptadecan]-13'-ene-2',11'-dione→(1'S,2'S,3'R,4'S,7'R,9'S,10'S)-4',9'-bis[(tert-butyldimethylsilyl)oxy]-1'-(methoxymethoxy)-10',14',17',17'-tetramethyl-11'-oxo-6'-oxaspiro[1,3-dithiane-2,12'-tetracyclo[11.3.1.0(3,10).0(4,7)]heptadecan]-13'-en-2'-yl benzoate→(1'S,2'S,3'R,4'S,7'R,9'S,10'S)-4',9'-bis[(tert-butyldimethylsilyl)oxy]-1'-(methoxymethoxy)-10',14',17',17'-tetramethyl-11',15'-dioxo-6'-oxaspiro[1,3-dithiane-2,12'-tetracyclo[11.3.1.0(3,10).0(4,7)]heptadecan]-13'-en-2'-yl benzoate→(1S,2S,3R,4S,7R,9S,10S,15S)-15-(benzyloxy)-4,9-bis[(tert-butyldimethylsilyl)oxy]-1-(methoxymethoxy)-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,9,12-tris(acetyloxy)-15-(benzyloxy)-1-(methoxymethoxy)-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,9,12-tris(acetyloxy)-15-hydroxy-1-(methoxymethoxy)-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,9,12-tris(acetyloxy)-15-{[(2R,3S)-2-(2-ethoxyethoxy)-3-phenyl-3-(phenylformamido)propanoyl]oxy}-1-(methoxymethoxy)-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-15-{[(2R,3S)-2-(2-ethoxyethoxy)-3-phenyl-3-(phenylformamido)propanoyl]oxy}-9-hydroxy-1-(methoxymethoxy)-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate

本站可供应的对应中间体

目录暂未收录该靶点的在售中间体 —— 可直接发起询价,需求会进入撮合池。

本页为中间体 CAS 注册档案:同 CAS 的多条路线登记已合并;后续供应商报价与买方需求以该 CAS 为主键撮合。